Increasing the bioavailability of oncology drugs with amorphous solid dosage formulations

Increasing the bioavailability of oncology drugs with amorphous solid dosage formulations

Brought to you by Lonza

Overview

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract. Most crystalline TKI drugs have pH-dependent solubility that affects their bioavailability in an oral dosage form. Consequently, natural variations in gastric pH, or variations due to eating or taking antacids, can significantly impact drug absorption and, in turn, therapeutic efficacy.

Alternative formulation techniques such as amorphous solid dispersion (ASD) can still deliver the convenience of a pill while reducing TKIs’ sensitivity to physiological variation. This ensures more consistent—and higher—bioavailability. This whitepaper outlines the challenges associated with pH-dependent solubility for oral TKI drugs and reviews how leveraging ASD formulation can help create more effective, patient-friendly drug products.

Key Objectives:

pH-dependent solubility of oral tyrosine kinase inhibitor drugs
Implications for bioavailability, therapeutic efficacy, and patient-friendliness
Amorphous solid dispersion as an alternative formulation approach to improve solubility
Methods for implementing ASD formulation

Brought to you by:

Please complete the form to download the white paper.

Forwarded this link? Clear the form

Email Address*

Salutation*

First Name*

Last Name*

Company*

Job Title

Address 1*

City*

State*

Zip / Post Code*

Country/Territory/Area*

Business Phone*

Do you have a bioavailability issue that you need help with?*

Would you like a Lonza expert to contact you about your needs?*

I would like to receive more information on products and services from the American Chemical Society

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.